ALTERDIAG raised €2M in Seed funding to develop innovative Rapid Diagnostic Tests
Paris, France, January 29, 2025 – ALTERDIAG, a private biotech company specializing in the development of rapid diagnostic tests targeting infectious disease pathogens, announces a €2 million seed funding round from Forepont Capital Partners, a New York-based venture capital firm specializing in healthcare and life sciences.
This fundraising coincides with the signing of a strategic partnership between ALTERDIAG and the Diagnostic Test Innovation and Development Core Facility at the Institut Pasteur in Paris. The collaboration aims to advance research and develop new rapid tests using lateral flow immunochromatography with single-domain antibodies (VHH). This funding will enable ALTERDIAG to launch its first R&D programs and expand its scientific and regulatory teams.
Karine Mignon Godefroy, General Manager of ALTERDIAG, stated : « Thanks to this successful seed funding round, ALTERDIAG is ideally positioned to become one of the most innovative players in the rapid diagnostics sector. This initial investment will allow us to begin our collaboration with the Institut Pasteur and address unmet medical needs. We are committed to innovating and developing products that will improve patient health. »
Ismail Kola, Ph.D, Chief Scientific Officer at FOREPONT CAPITAL PARTNERS, added : « Forepont is proud to support the cutting-edge technological advancements developed by the Institut Pasteur and AlterDiag. We firmly believe in the potential of VHH to overcome the limitations of conventional monoclonal antibodies currently used in rapid diagnostic tests. »
About AlterDiag:
AlterDiag is an ambitious French startup founded in 2024 by Dr. Karine Mignon-Godefroy and M. Cédric Béchet that aims to provide healthcare professionals and patients with fast, high-performance, easy-to-use and inexpensive diagnostic tools that can be performed directly in healthcare centers or at home. Dr. Mignon-Godefroy, General Manager of AlterDiag, holds a PhD in Immunology from Université Pierre Marie Curie and an Executive MBA from ESCP Europe. She has over 30 years’ experience in the diagnostic market, during which time she held the positions of Vice-President Head of R&D for new innovative product development, as well as Head of Industrial Partnerships & Start-ups creation at the Institut Pasteur.
AlterDiag’s ambition is to be recognized as a major player in the global market for innovative rapid tests, thanks to the use of high-performance technology that responds to the various proven medical needs in the field of infectious diseases and enables personalized care tailored to each patient.
AlterDiag aims to find solutions that meet WHO expectations for diseases of interest. This strategic positioning will enable the company to respond rapidly to future epidemics.
To achieve its ambition, AlterDiag has already raised its first round of financing with Forepont Capital Partners, a Franco-American investment fund specializing in the financing of biotechs, medtechs and disruptive start-ups in the healthcare sector.
About Forepont Capital Partners:
Forepont Capital Partners is a healthcare and life science venture capital firm based in New York with a strong presence in Europe. Forepont has developed partnerships with industry leaders, physicians, key opinion leaders, universities, hospitals and pharmaceutical groups, mainly in neurology. Forepont invests in early-stage companies whose science and technology are intended to positively impact the lives of patients. Forepont provides scientific, technological, financial and operational support to improve portfolio company performance, leveraging their talents with its know-how and global ecosystem. To learn more, please visit www.forepont.com